STOCK TITAN

[Form 4] KORU Medical Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

KORU Medical Systems director Matin Shahriar reported a purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. Following this transaction the reporting person beneficially owns 91,520 shares. The filing was submitted on Form 4 and signed by an attorney-in-fact.

Il direttore di KORU Medical Systems Matin Shahriar ha riferito un acquisto di 3.916 azioni di KORU Medical Systems, Inc. (KRMD) il 02/10/2025 ad un prezzo riportato di $3.83 per azione. A seguito di questa operazione la persona che segnala detiene beneficiamente 91.520 azioni. La comunicazione è stata presentata sul Modulo 4 e firmata da un procuratore-in-fatto.

El director de KORU Medical Systems, Matin Shahriar, reportó una compra de 3.916 acciones de KORU Medical Systems, Inc. (KRMD) el 10/02/2025 a un precio reportado de $3.83 por acción. Tras esta transacción, la persona que informa posee de manera beneficiosa 91.520 acciones. La presentación fue presentada en el Formulario 4 y firmada por un apoderado.

KORU Medical Systems의 이사 Matin ShahriarKRMD 표기로 된 KORU Medical Systems, Inc.의 3,916주를 2025-10-02$3.83의 주당 가격으로 매수했다고 보고했습니다. 이 거래 후 보고자는 91,520주를 실질적으로 보유하게 됩니다. 제출은 Form 4로 이루어졌으며 대리인이 서명했습니다.

Le directeur de KORU Medical Systems, Matin Shahriar, a annoncé l'achat de 3 916 actions de KORU Medical Systems, Inc. (KRMD) le 02/10/2025 à un prix rapporté de $3,83 par action. Suite à cette opération, la personne déclarant détient de manière bénéficiaire 91 520 actions. La déclaration a été déposée sur le formulaire 4 et signée par un mandataire.

Der Direktor von KORU Medical Systems, Matin Shahriar, meldete den Erwerb von 3.916 Stammaktien von KORU Medical Systems, Inc. (KRMD) am 02.10.2025 zu einem berichteten Preis von $3.83 pro Aktie. Nach dieser Transaktion hält die meldende Person vorteilhaft 91.520 Aktien. Die Einreichung wurde auf Formular 4 eingereicht und von einem Bevollmächtigten unterzeichnet.

مدير KORU Medical Systems، Matin Shahriar، أبلغ عن شراء 3,916 أسهم من KORU Medical Systems, Inc. (KRMD) في 02/10/2025 بسعر مذكور قدره $3.83 للسهم الواحد. عقب هذه المعاملة يمتلك الشخص المبلغ بيانياً 91,520 سهمًا بشكل منفعلي. تم تقديم الإبلاغ على النموذج 4 وتوقيعه بواسطة وكيل قانوني.

KORU Medical Systems 董事 Matin Shahriar2025-10-02 以每股 $3.83 的报导价格,报告购买了 3,916 股 KORU Medical Systems, Inc. (KRMD) 的股票。此笔交易完成后,汇报人实际持有 91,520 股。该申报表以 Form 4 提交,并由代理人签署。

Positive
  • Director purchase of 3,916 shares at $3.83 indicates insider acquisition
  • Total beneficial ownership reported as 91,520 shares after the transaction
Negative
  • None.

Insights

Director purchased 3,916 shares at $3.83, increasing holdings to 91,520 shares.

This Form 4 discloses an open-market purchase by director Matin Shahriar on 10/02/2025. The filing shows the transaction code "A" (acquisition) and lists the resulting beneficial ownership as 91,520 shares.

The record includes a standard attorney-in-fact signature and a customary disclaimer that the filer does not admit beneficial ownership for Section 16 purposes. No derivative transactions or additional changes were reported.

Il direttore di KORU Medical Systems Matin Shahriar ha riferito un acquisto di 3.916 azioni di KORU Medical Systems, Inc. (KRMD) il 02/10/2025 ad un prezzo riportato di $3.83 per azione. A seguito di questa operazione la persona che segnala detiene beneficiamente 91.520 azioni. La comunicazione è stata presentata sul Modulo 4 e firmata da un procuratore-in-fatto.

El director de KORU Medical Systems, Matin Shahriar, reportó una compra de 3.916 acciones de KORU Medical Systems, Inc. (KRMD) el 10/02/2025 a un precio reportado de $3.83 por acción. Tras esta transacción, la persona que informa posee de manera beneficiosa 91.520 acciones. La presentación fue presentada en el Formulario 4 y firmada por un apoderado.

KORU Medical Systems의 이사 Matin ShahriarKRMD 표기로 된 KORU Medical Systems, Inc.의 3,916주를 2025-10-02$3.83의 주당 가격으로 매수했다고 보고했습니다. 이 거래 후 보고자는 91,520주를 실질적으로 보유하게 됩니다. 제출은 Form 4로 이루어졌으며 대리인이 서명했습니다.

Le directeur de KORU Medical Systems, Matin Shahriar, a annoncé l'achat de 3 916 actions de KORU Medical Systems, Inc. (KRMD) le 02/10/2025 à un prix rapporté de $3,83 par action. Suite à cette opération, la personne déclarant détient de manière bénéficiaire 91 520 actions. La déclaration a été déposée sur le formulaire 4 et signée par un mandataire.

Der Direktor von KORU Medical Systems, Matin Shahriar, meldete den Erwerb von 3.916 Stammaktien von KORU Medical Systems, Inc. (KRMD) am 02.10.2025 zu einem berichteten Preis von $3.83 pro Aktie. Nach dieser Transaktion hält die meldende Person vorteilhaft 91.520 Aktien. Die Einreichung wurde auf Formular 4 eingereicht und von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Matin Shahriar

(Last) (First) (Middle)
C/O KORU MEDICAL SYSTEMS, INC.
100 CORPORATE DRIVE

(Street)
MAHWAH NJ 07430

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 A 3,916 A $3.83 91,520 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.
/s/ Thomas Adams- Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Matin Shahriar report on Form 4 for KRMD?

The filing reports an acquisition of 3,916 shares of KRMD on 10/02/2025 at a price of $3.83 per share.

How many KRMD shares does the reporting person own after the transaction?

The Form 4 states beneficial ownership of 91,520 shares following the reported purchase.

What was the transaction code and what does it indicate?

The transaction is coded "A", which on Form 4 indicates an acquisition of securities.

When was the Form 4 transaction dated?

The transaction date listed on the Form 4 is 10/02/2025.

Who signed the Form 4 filing?

The filing is signed by Thomas Adams, identified as Attorney-in-Fact, on 10/02/2025.
Koru Med Sys

NASDAQ:KRMD

KRMD Rankings

KRMD Latest News

KRMD Latest SEC Filings

KRMD Stock Data

181.70M
42.38M
8.29%
55.73%
2.53%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MAHWAH